Tetraacuo-bis-(N,N-dimethylacetamide-o)magnesium(II) chloride dihydrate. An option to improve magnesium efecto on phosphatase stimulation and albumin binding

Abstract

Magnesium compounds became relevant since the discovery that this element is essential and its deficiency causes several diseases. From these findings, magnesium supplementation became a pharmacologically important issue that prompted the search for new drugs. There are many commercial formulations for restoring electrolyte balance, nutrition, learning, Alzheimer's disease, mood disorder, pain, etc. Magnesium is found in ALP and is known to be able to stimulate its activity. Because of that, there is a great interest in a study of the activity of magnesium compounds as a drug for osteoporosis. Metal complexes are known to improve the bioavailability and the pharmacological performance of drugs. Thus, we combine the pharmacological ability of magnesium together with the potential biological activity of N,N-dimethylacetamide (a common solvent used in pharmaceutical preparations). The present study reports the chemical syntheses of [Mg(DMA)2(H2O)4]Cl2.2H2O complex and the clinical potential implication as phosphatase stimulator. In a typical phosphatase assay containing p-nitrophenyl phosphate, the kinetic constants (Km and Kcat) were calculated through Michaelis-Menten assumptions and the activities of the magnesium complex, alkaline phosphatase and magnesium chloride had been compared. The compound can activate ALP hence suggesting that it could regulate bone matrix formation. Albumin binding experiments were also performed and revealed a better interaction than the well-known magnesium chloride salt.